Pharmacoepidemiology of immune thrombocytopenia: Protocols of FAITH and CARMEN Studies

Therapie

Volumn 69, Issue 5, 2014, Pages 437-448

  Moulis, Guillaume ^a,b,c   Sailler, Laurent ^a,b,c   Adoue, Daniel ^a   Lapeyre Mestre, Maryse ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSERM   (France)

Author keywords

Epidemiology; Immune thrombocytopenia; Pharmacoepidemiology; Rituximab; Thrombopoietin receptor agonist

Indexed keywords

CORTICOSTEROID; RITUXIMAB;

ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; FRANCE; HUMAN; PATIENT COMPLIANCE; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; ADULT; EPIDEMIOLOGY; PROCEDURES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; STATISTICS AND NUMERICAL DATA;

ADULT; EPIDEMIOLOGIC RESEARCH DESIGN; FRANCE; HUMANS; PHARMACOEPIDEMIOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84907943036     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2014056     Document Type: Article

References (57)

1. Rodeghiero F, Stasi R, Gernsheimer T et al,. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-93
2. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006; 133: 364-74
3. Terrell DR, Beebe LA, Vesely SK et al,. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010; 85: 174-80
4. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909-13
5. Neylon AJ, Saunders PWG, Howard MR et al,. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122: 966-74
6. Schoonen WM, Kucera G, Coalson J et al,. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009; 145 (2): 235-4. Erratum in: Br J Haematol 2009 Sep; 147(1): 157
7. Cohen YC, Djulbegovic B, Shamai-Lubovitz O et al,. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160: 1630-8
8. Portielje JE, Westendorp RG, Kluin-Nelemans HC et al,. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-54
9. Michel M, Rauzy OB, Thoraval FR et al,. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am J Hematol 2011; 86: 980-4
10. Grimaldi-Bensouda L, Michel M, Aubrun E et al,. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood 2012; 120: 4938-44
11. Kühne T, Berchtold W, Michaels LA et al,. Newly diagnosed immune thrombocytopenia in children and adults, a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011; 96: 1831-7
12. Provan D, Stasi R, Newland AC et al,. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86
13. Neunert C, Lim W, Crowther M et al,. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-207
14. Ghanima W, Godeau B, Cines DB et al,. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012; 120: 960-9
15. Kojouri K, Vesely SK, Terrell DR et al,. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-34
16. Vianelli N, Galli M, de Vivo A et al,. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90: 72-7
17. Schwartz J, Leber MD, Gillis S et al,. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003; 72: 94-8
18. Mikhael J, Northridge K, Lindquist K et al,. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review. Am J Hematol 2009; 84: 743-8
19. Vianelli N, Palandri F, Polverelli N et al,. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013; 98: 875-80
20. Thomsen RW, Schoonen WM, Farkas DK et al,. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med 2009; 151: 546-55
21. Arnold DM, Heddle NM, Carruthers J et al,. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012; 119: 1356-62
22. Auger S, Duny Y, Rossi JF et al,. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012; 158: 386-98
23. Godeau B, Porcher R, Fain O et al,. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004
24. Medeot M, Zaja F, Vianelli N et al,. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol 2008; 81: 165-9
25. Patel VL, Mahévas M, Lee SY et al,. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119: 5989-95
26. Arnold DM, Dentali F, Crowther MA et al,. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33
27. Moulis G, Sailler L, Sommet A et al,. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol 2014; 89: 41-6
28. Moulis G, Sailler L, Sommet A et al,. Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. Eur J Haematol 2013; 90: 438-9
29. th, 2014 (14 pages)
30. th, 2014
31. th, 2014 (59 pages)
32. th, 2014 (79 pages)
33. Oshima Y, Yuji K, Tanimoto T et al,. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Intern Med 2013; 52: 2193-201
34. Tuppin P, de Roquefeuil L, Weill A et al,. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010; 58: 286-90
35. th, 2014 (56 pages)
36. Arnaud L, Fagot JP, Mathian A et al,. Incidence and prevalence of systemic lupus erythematosus: a 2010 nation-wide population based study using French national administrative databases. Arthritis Rheum 2013; 65: 1067. [abstract]
37. Tuppin P, Cuerq A, de Peretti C et al,. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. Arch Cardiovasc Dis 2013; 106: 570-85
38. Quantin C, Benzenine E, Hägi M, et al. Estimation of national colorectal-cancer incidence using claims databases. J Cancer Epidemiol 2012; 2012: 298369
39. Dupouy J, Fournier J-P, Jouanjus É et al,. Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns - a cohort study. Eur Neuropsychopharmacol 2014; 24: 192-9
40. Neumann A, Maura G, Weill A et al,. Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf 2014; 23: 240-50
41. Neumann A, Weill A, Ricordeau P et al,. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-62
42. Weill A, Païta M, Tuppin P et al,. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010; 19: 1256-62
43. th, 2014
44. th, 2014
45. th, 2014
46. th, 2014 (94 pages)
47. th, 2014
48. th, 2014
49. Gottenberg JE, Ravaud P, Bardin T et al,. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62: 2625-32
50. Leandro MJ, Cambridge G, Ehrenstein MR et al,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20
51. th, 2014
52. Bannay A, Chaignot C, Blotière P-O, et al. Score de Charlson à partir des données du Sniiram chaînées au PMSI: faisabilité et valeur pronostique sur la mortalité à un an. Rev Epidemiol Sante Publique 2013; 61: S9 [abstract]
53. th, 2014
54. Khellaf M, Michel M, Schaeffer A et al,. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005; 90: 829-32
55. Ware JE Jr, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) Project. J Clin Epidemiol 1998; 51: 903-12
56. Leplège A, Ecosse E, Verdier A et al,. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998; 51: 1013-23
57. th, 2014